# Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

> **NCT07057778** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Iguratimod
- **DRUG:** low-dose rituximab

## Key facts

- **NCT ID:** NCT07057778
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-07-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057778, "Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07057778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*